Lipofen Articles
Abbott Lab’s 4th-quarter 2009 profit flat due to charges, buts sales rise nearly 11% driven by Humira; still open to buys
28 January 2010
EU Commission delays decision on Abbott’s acquisition of Solvay; clears Archimedes takeover
25 January 2010
Abbott in settlement deal with Teva over Tricor generic
1 December 2009
Abbott to buy Solvay pharmaceuticals business for 4.5 billion euros, but will bidding war cease?
28 September 2009
Abbott and AZ set to co-promote TriLipix
5 June 2009
Japan stock market week to June 1, 2009
3 June 2009
Profit plummets 55% for Solvay in recession
15 May 2009
53% jump in 1st-qtr profit for Abbott
15 April 2009
Oscient's 2008 loss more than doubles to $64.7M
3 April 2009
Fenofibrate cuts CV risk 27% in some patients
9 March 2009
Abbott's 4th-qtr profit jumps 28% on strong sales of Humira and divestment of spinal products unit
26 January 2009
FDA approves Abbott's cholesterol drug
22 December 2008
Abbott pays $184M to settle court case
1 December 2008
Negative press has compromised Vytorin as first-line therapy; DR
17 November 2008
Canada's Biovail files ANDA for fenofibrate
8 September 2008
AstraZeneca's Crestor to be co-promoted with Abbott Labs in USA
1 September 2008
Zetia "could be expensive placebo," ACC hears
7 April 2008
Abbott's TriLipix improves key lipid measures
7 April 2008
Abbott gets $100M under Simcor deal
24 March 2008
Fournier challenges Teva's US generic TriCor
10 March 2008
Sciele launches Fenoglide in USA
3 March 2008
Teva files ANDA for Fournier/Solvay's fenofibrate
4 February 2008
Abbott Labs returns to profit in 4th-qtr 2007
28 January 2008
Oscient's 4th-qtr 2007 revenues rise to $25M
21 January 2008
Solvay sells French site of Fournier
10 December 2007
Solvay
19 November 2007
Solvay negotiating sale of Fournier's Synkem
19 November 2007
Abbott Labs' 3rd-qtr 2007 net earnings flat
29 October 2007
Oscient's 3rd-qtr 2007 income rises to $15.5M
22 October 2007
Indonesia to begin copycat Tamiflu production
8 October 2007
Dual Crestor/ABT-335 pill to enter Ph III
10 September 2007
LifeCycle to initiate Ph II LCP-AtorFen trial
23 July 2007
Abbott Labs' 2nd-qtr 2007 profit soars 61.4%
23 July 2007
ProEthic in US deal for Lipofen
16 July 2007
Oscient's 1st-qtr income doubles on Antara sales
28 May 2007
LifeCycle and Sciele agree licensing deal
7 May 2007
Abbott's 1st-qtr profit drops 19% to $697.5M
23 April 2007
SCLOR starts PKC study of CDT-fenofibrate
16 April 2007
Solvay's 2006 sales rise 10% to $12.35 billion
26 February 2007
Abbott suffers 4th-qtr $0.37 LPS on Kos buy
5 February 2007
Solvay withdraws Synordia EMEA submission due to time constraints
18 December 2006
Pfizer drops star drug candidate after DSMB points out excessive mortality in Ph III trial
11 December 2006
Solvay's 3rd-qtr 2006 income rises 6%
6 November 2006
Biotech stocks in holding pattern for August, says Burrill report
18 September 2006
Oscient completes $78M buy of Reliant's Antara
28 August 2006
Solvay's operating profit leaps 40%
7 August 2006
Abbott's 2nd qtr profit drops on Guidant buy
24 July 2006
Merck/S-P's Zetia gets expanded US label
19 June 2006
2005: "difficult year for SkyePharma," chairman
24 April 2006
Solvay's 2005 revenue reaches 8.5 B euros
27 February 2006
Solvay to shed 400 jobs in France
13 February 2006
Abbott:13.4% 4th-qtr 2005 EPS growth, as expected
6 February 2006
Stock Commentary - New York week to Nov 28
5 December 2005
Final FDA approval for Teva's fenofibrate
23 May 2005
FDA OKs Triglide
16 May 2005
Fournier's 2004 drug sales boosted by US
28 February 2005
SkyePharm and First Horizon are closer to FDA approval
14 February 2005
Solvay eyeing up Fournier purchase?
13 December 2004
FDA OKs new form of Abbott's TriCor
15 November 2004
Abbott's 2nd-qtr 2004 sales rise 14%
19 July 2004
Generics' major role in new French Rx policy
24 May 2004
Abbott sees 13.9% rise in sales for 1st-qtr 2004
19 April 2004
Indofarma and Kimia Farma to merge?
15 March 2004
PT Kalbe Farma forecasts 15% growth
16 February 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
PT Kalbe aims to boost sales 15%
10 November 2003
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
Indonesian commission to monitor drug prices
23 June 2003
Kimia Farma forecasts higher 2003 sales
26 May 2003
Sale of PT Indofarma delayed by Iraqi war situation?
14 April 2003
Fournier forecasts growth in Singapore
17 March 2003
Kimia Farma ready to sell stake in RAF
24 February 2003
Abbott's profits up 2%, forecasts lowered
27 January 2003
Indonesian pharma market data
15 July 2002
Kimia Farma sale criticized
24 June 2002
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
